What is Bioniq?
Founded in 2019, Bioniq operates at the intersection of biotechnology and consumer wellness. The company distinguishes itself by utilizing blood biomarker data to formulate highly personalized supplement regimens for its users. By integrating artificial intelligence with clinical-grade diagnostics, Bioniq provides a bespoke health experience that moves beyond generic wellness trends. Its market position is defined by a commitment to precision medicine, catering to a growing demographic of health-conscious consumers who demand evidence-based, data-driven solutions for their nutritional needs. As the industry shifts toward hyper-personalization, Bioniq's ability to synthesize complex biological data into actionable health insights provides a significant competitive advantage.
How much funding has Bioniq raised?
Bioniq has raised a total of $22.8M across 2 funding rounds:
Series A
$7.8M
Series B
$15M
Series A (2021): $7.8M with participation from OKS Group incorporated
Series B (2024): $15M led by Unbound and HV Capital
Key Investors in Bioniq
HV Capital
HV Capital is a prominent venture firm based in Germany that specializes in supporting early-stage and growth-stage companies with a focus on digital innovation.
Unbound
Unbound is a strategic investment firm that partners with high-growth companies to provide the capital and expertise necessary for scaling operations.
OKS Group incorporated
OKS Group is a diversified investment entity that provides capital and operational support to businesses across various sectors, including technology and health services.
What's next for Bioniq?
With the successful closure of this major strategic investment, Bioniq is well-positioned to accelerate its international expansion and deepen its research and development capabilities. The company is expected to focus on refining its AI algorithms to provide even more granular health insights, potentially expanding its service offerings to include broader diagnostic capabilities. Furthermore, the influx of capital will likely support the scaling of its supply chain and digital platform, allowing Bioniq to capture a larger share of the personalized nutrition market. As the firm transitions into this next phase of maturity, the focus will remain on maintaining clinical rigor while scaling its user base across key global markets.
See full Bioniq company page
